Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Resverlogix Corp. T.RVX

Alternate Symbol(s):  T.RVX.W.A | RVXCF

Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.

The Market Herald Price Sensitive
{{currentVideo.title}} {{currentVideo.relativeTime}}
{{currentVideo.storiesTitle}}:
{{story.companySymbol}}
{{story.companySymbol}} {{story.headline}}
< Previous bulletin
Next bulletin >
View modes: 
@ the Bell: Commodities drag TSX stocks lower as recession fears grip global markets
Canada’s main stocks index slid more than 1 per cent on Tuesday, following up a bigger market selloff as global recession worries came to the forefront, while energy stocks dipped along with oil... read article.
@ the Bell: Markets start second half of '22 trading on upbeat note
Canada’s resources-heavy stock index rose on Monday as oil prices gained and investors returned from a long weekend to purchase riskier assets that have been battered by concerns over a global... read article.

Neovasc Announces Direct Sales Operations in United Kingdom

Fred Colen, Neovasc President and Chief Executive Officer, said, “We are pleased to expand our direct presence into the United Kingdom and want to thank our partners at Healthcare 21 for their excellent foundational efforts supporting the early growth of Reducer. We are now poised to provide even deeper support with a full-time dedicated team in the U.K. and intend to continue to invest in clinical research and field personnel to support patients, physicians, and hospitals.” ...read more
Buzz on the Bullboards: Sizzling sector highlights
It has been a sizzling few days recently for most of North America, both weather-wise and for investing discussions. The markets face a rate hike in the U.S., ongoing inflation, rising oil and... read article.

New Press Release - Resverlogix Announces Voting Results from the 2022 Meeting of Shareholders

CALGARY, Alberta, June 21, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix”, or the "Corporation") (TSX:RVX) today held its Annual Meeting of Shareholders (the “Meeting”) in Calgary, Alberta. During business proceedings at the Meeting, shareholders elected five (5) Board members...read article.

RE:problems solved!

up a whooooole HALF of a penny! .005c.  Wow. the board must be burnin up the airwaves making calls telling anyone who will listen that WE ARE FOR SALE! never mind that we just dropped 11...read more

problems solved!

thanks to the brialliant brain trust at agoracommie!  our problems are SOLVED! We're for sale!!!!!!!!!!!  yippee!!!!!! see us run!  we're announcing to the world that we are for...read more

RE:New Press Release posted by Stockhouse - June 8, 2022

AMEN! GV Jk  rate and reply

RE:New Press Release posted by Stockhouse - June 8, 2022

Does that mean the brain trust at RVX finally figured out how our drug works? sweet.  Seems like only yesterday we were announcing we are a bromodomain inhibitor. Accidentally of course. By...read more

New Press Release posted by Stockhouse - June 8, 2022

They come out with this kind of news when there is such a precipitous decline in the SPP. Can't make these guys out. They keep pumping studies in prestigious scientific journals about apabetalon...read more

New Press Release - Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors

CALGARY, Alberta, June 08, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled “Breaking boundaries: Pan BETi disrupt 3D chromatin structure, BD2-selective BETi are strictly epigenetic transcriptional regulators” in the...read article.

RE:RE:RE:RE:AGM Votes

great question GV!  i bet they're current only if the underwriter takes toilet paper as a form of payment...  like you said, i can't believe there isnt a class action against these...read more

RE:RE:RE:AGM Votes

GENERAL, DO YOU THINK THEY HAVE ENUF SENSE TO PAY THEIR PREMIUMS ON THEIR ERRORS AND OMMISSIONS POLICY? Jk  rate and reply

RE:RE:AGM Votes

down ANOTHER 12% today.  FANTATIC work team! one of our biggest drops %-wise, again!  another new record! I wonder if its the fine people shorting the stock who are participating in these...read more

RE:RE:AGM Votes

Excellent fuzzy! Toinv  rate and reply

RE:AGM Votes

Done Toni + I would also suggest that everyone send a e-mail to him. don@resverlogix.com   Sent mine this morning. "Truth Don"   "You should try it one of these...read more

AGM Votes

Hi folks. As everyone knows attendance is being restricted at the AGM again this year under the guise of Covid. Censorship is the tool used when the lie loses it’s power. (G. Orwell???) I am...read more

RE:RE:Q&A with Sarah Re, May 9 2022 News Release

JUST THINKING, THAT IF MESS HAD OCCURED IN THE STATES THE CLASS ACTION BAR WOULD HAVE BEEN ALL OVER THIS INJUSTICE YEARS AGO! Jk  rate and reply

RE:RE:Q&A with Sarah Re, May 9 2022 News Release

***Sarah: GV, the study has not been abandoned – but concluded early without completion as originally planned. It is my understanding that any data from this study will be potentially presented at a...read more

RE:Q&A with Sarah Re, May 9 2022 News Release

June 2, 2022: GV: Thank you again, Sarah.  Are you at liberty to tell me how many were recruited for the Covid 19 Open-label Study before it was terminated?  Sarah: I do not have...read more

RE:Q&A with Sarah Re, May 9 2022 News Release

,,you are a tuff one GV,,,good contact,,,,,and of course they refuse to comment and or provide the material data which has effected share price. The market is in the know,,,,,they have info around the...read more

RE:RE:Q&A with Sarah Re, May 9 2022 News Release

Management and the board are a complete waste of money.   rate and reply

RE:Q&A with Sarah Re, May 9 2022 News Release

If they concluded the study before it was completed, that sounds like they saw no benefit whatsoever, so continuing it would have been a waste of money. JMO  rate and reply

RE:Q&A with Sarah Re, May 9 2022 News Release

Thanks for posting GV! that make my fcuking blood boil.  Massive difference between inpatient and outpatient.  Looks like a shytti trial design, AGAIN. and of course, Univerity of rvx...read more